|
||||||||
![]() |
||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]()
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
The vector sequence has been compiled using the information from sequence databases, published literature, and other sources, together with partial sequences obtained by Evrogen. This vector has not been completely sequenced. |
|||||||||||||||||||||||||||||||||||||||||||||||||
![]() Download
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
pTagYFP-actin is a mammalian expression vector encoding TagYFP-actin fusion protein (see TagYFP description). The vector can be used for fluorescent labeling of β-actin in living cells.
TagYFP codon usage is optimized for high expression in mammalian cells, i.e. humanized (Haas et al., 1996). Human cytoplasmic β-actin is fused to the TagYFP C-terminus. To increase mRNA translation efficiency, Kozak consensus translation initiation site is generated upstream of TagYFP-actin coding sequence [Kozak, 1987].
pTagYFP-actin can be used as a source of TagYFP-actin hybrid sequence. The vector backbone contains unique restriction sites that permit it excision and further insertion into expression vector of choice.
Note: The plasmid DNA was isolated from dam+-methylated E.coli. Therefore some restriction sites are blocked by methylation. If you wish to digest the vector using such sites you will need to transform the vector into a dam- host and make fresh DNA.
The vector backbone also contains immediate early promoter of cytomegalovirus (PCMV IE) for protein expression, SV40 origin for replication in mammalian cells expressing SV40 T-antigen, pUC origin of replication for propagation in E. coli, and f1 origin for single-stranded DNA production. SV40 polyadenylation signals (SV40 poly A) direct proper processing of the 3' end of the reporter mRNA.
SV40 early promoter (PSV40) provides neomycin resistance gene (Neor) expression to select stably transfected eukaryotic cells using G418. Bacterial promoter (P) provides kanamycin resistance gene expression (Kanr) in E. coli. Kanr/Neor gene is linked with herpes simplex virus (HSV) thymidine kinase (TK) polyadenylation signals.
Expression in mammalian cells
pTagYFP-actin can be transfected into mammalian cells by any known transfection method. CMV promoter provides strong, constitutive expression of the TagYFP-actin fusion in eukaryotic cells. If required, stable transformants can be selected using G418 [Gorman, 1985].
Propagation in E. coli
Suitable host strains for propagation in E. coli include DH5alpha, HB101, XL1-Blue, and other general purpose strains. Plasmid incompatibility group is pMB1/ColE1. The vector confers resistance to kanamycin (30 μg/ml) to E. coli hosts. Copy number in E. coli is about 500.
Location of features
PCMV IE: 1-589
Enhancer region: 59-465
TATA box: 554-560
Transcription start point: 583
Kozak consensus translation initiation site: 606-616
TagYFP
Start codon (ATG): 613-615
Last amino acid in TagYFP: 1327-1329
Beta-Actin: 1351-2478
Stop codon: 2476-2478
SV40 early mRNA polyadenylation signal
Polyadenylation signals: 2639-2644 & 2668-2673
mRNA 3' ends: 2677 & 2689
f1 single-strand DNA origin: 2736-3191
Eukaryotic promoter for expression of Kanr gene
-35 region: 3253-3258
-10 region: 3276-3281
Transcription start point: 3288
SV40 origin of replication: 3532-3667
SV40 early promoter
Enhancer (72-bp tandem repeats): 3365-3436 & 3437-3508
21-bp repeats: 3512-3532, 3533-3553 & 3555-3575
Early promoter element: 3588-3594
Major transcription start points: 3584, 3622, 3628 & 3633
Kanamycin/neomycin resistance gene
Neomycin phosphotransferase coding sequences:
Start codon (ATG): 3716-3718
Stop codon: 4508-4510
G->A mutation to remove Pst I site: 3898
C->A (Arg to Ser) mutation to remove BssH II site: 4244
Herpes simplex virus (HSV) thymidine kinase (TK) polyadenylation signal
Polyadenylation signals: 4746-4751 & 4759-4764
pUC plasmid replication origin: 5095-5738
Evrogen FP-related products are intended for research use only and covered by Evrogen Patents and/or Patent applications pending. By use of these products, you accept the terms and conditions of the applicable Limited Use Label License.
The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839, and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.
To the best of our knowledge, these products do not require a Material Safety Data Sheet. However, all the properties of these products (and, if applicable, each of their components) have not been thoroughly investigated. Therefore, we recommend that you use gloves and eye protection, and wear a laboratory coat when working with these products.
|
Copyright 2002-2008 Evrogen. All rights reserved. Evrogen JSC, 16/10 Miklukho-Maklaya str., Moscow, Russia, +7(495)4298020, e-mail:evrogen@evrogen.com |